Identification of Biomarkers for Prostate Cancer
Abstract
BACKGROUND: Prostate cancer (PCa) was the second most common type of cancer and the fifth leading cause of cancer-related death in men. The great challenge for physicians is being able to accurately predict PCa prognosis and treatment response in order to reduce PCa-specific mortality while avoiding overtreatment by identifying of when to intervene, and in which patients.
CONTENT: Currently, PCa prognosis and treatment decision of PCa involved digital rectal examination, Prostate-Speciic Antigens (PSA), and subsequent biopsies for histopathological staging, known as Gleason score. However, each procedure has its shortcomings. Efforts to find a better clinically meaningful and non-invasive biomarkers still developed involving proteins, circulating tumor cells, nucleic acids, and the ‘omics' approaches.
SUMMARY: Biomarkers for PCa will most likely be an assay employing multiple biomarkers in combination using protein and gene microarrays, containing markers that are differentially expressed in PCa.
KEYWORDS: prostate cancer, PSA, biomarkers, nomograms, miRNA, proteomic, genomic, metabolomic
Full Text:
PDFReferences
National Cancer Institute [homepage on the internet]. Bethesda: Prostate Cancer [cited 2014 Dec 4]. Available from: http://www.cancer.gov/.
Stewart BW, Wild CP. World Cancer Report 2014. Lyon: IARC; 2014, NLMID.
Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA. Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int. 2013; 1: 47-58, CrossRef.
Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancerpart I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999; 91: 1017-24, CrossRef.
Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 2003; 98: 1169-78, CrossRef.
De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, et al. Human prostate cancer precursors and pathobiology. Urology. 2001; 62 (5 Suppl 1): 55-62, CrossRef.
Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Robert CB, et al. Contemporary risk proile of prostate cancer in the United States. J Natl Cancer Inst. 2009; 101: 1280-3, CrossRef.
Martin NE, Mucci LA, Loda M, Depinho RA. Prognostic determinants in prostate cancer. Cancer J. 2011; 17: 429-37, CrossRef.
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-13, CrossRef.
Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res. 2008; 170: 49-59, CrossRef.
Rosenstein BS. Identiication of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics 2011; 12: 267-75, CrossRef.
Aumüller G. Prostate Gland and Seminal Vesicles. Berlin-Heidelberg: Springer-Verlag; 1979, link.
Moore KL, Agur AMR, Dalley AF. Clinically Oriented Anatomy. 4th ed.Philadelphia: Lippincott Williams & Wilkins; 1999, NLMID.
Steive H. Männliche Genitalorgane. In: Steive H, editor. Handbuch der mikroskopischen Anatomie des Menschen. Vol. VII Part 2. Berlin: Springer; 1930. p.1-399, NLMID.
Wikipedia [homepage on the Internet]. Prostate Cancer; 2015 [cited 2014 Dec 8]. Available from: http://en.wikipedia.org/.
Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 1996; 28: 251-65, CrossRef.
Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001; 1: 34-45, CrossRef.
Hietanen E, Bartsch H, Béréziat JC, Camus AM, McClinton S, Eremin O, et al. Diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study. Eur J Clin Nutr. 1994; 48: 575-86, PMID.
Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998; 78: 547-81, PMID.
Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA 1995; 92: 5258-65, CrossRef.
De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inlammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-92, CrossRef.
Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998; 22: 1073-7, CrossRef.
Feneley MR, Young MP, Chinyama C, Kirby RS, Parkinson MC. Ki-67 expression in early prostate cancer and associated pathological lesions. J Clin Pathol 1996; 49: 741-8, CrossRef.
Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res. 2002; 62: 6405-9, PMID.
Kim Y, Kislinger T. Novel approaches for the identification of biomarkers of aggressive prostate cancer. Genom Med. 2013; 5: 56-67, CrossRef.
Assinder SJ, Nicholson H. Prostate Disease: Prostate hyperplasiaand prostate cancer and prostatitis. In: Kandeel EF, editor. Pathophysiology and Treatment of Male Sexual and Reproductive Dysfunction. New York: Marcel Dekker Inc; 2007. p. 423-39, CrossRef.
Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med. 2012, 4: 127rv3, CrossRef.
Papsidero LD, Wojcieszyn JW, Horoszewicz JS, Leong SS, Murphy GP, Chu TM. Isolation of prostatic acid phosphatase-binding immunoglobulin G from human sera and its potential for use as a tumor-localizing reagent. Cancer Res. 2008; 40: 3032-5, PMID.
Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 1980; 40: 4658-62, PMID.
Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL, et al. Prostate volume and prostate-specific antigen levels in men enrolled in a lagre screening trial. Urology. 2006; 68: 352-6, CrossRef.
Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005; 294: 66-70, CrossRef.
Sardana G, Diamandis E. Biomarkers for the diagnosis of new and recurrent prostate cancer. Biomark Med. 2012; 6: 587-96, CrossRef.
Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta. 2002; 315: 71-97, CrossRef.
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-46, CrossRef.
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA. 1998; 279: 1542-7, CrossRef.
Finne P, Auvinen A, Määttänen L, Tammela TL, Ruutu M, Juusela H, et al. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 μg per liter. Eur Urol. 2008; 54: 362-70, CrossRef.
Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer. 2007; 43: 1918-26, CrossRef.
Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111: 58-64, PMID.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280: 969-74, CrossRef.
Glass AS, Porten SP, Bonham M, Tran TC, Cowan JE, Punnen S, et al. Active surveillance: Does serial prostate biopsy increase histological inlammation? Prostate Cancer Prostatic Dis. 2013, 16: 165-9, CrossRef.
Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJ, Tindall DJ, et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumors and in normal breast secretions. Br J Cancer. 2000; 82: 361-7, PMID.
Yousef GM, Diamandis E. The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev. 2001; 22: 184-204, CrossRef.
Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A, Lümmen G, et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-conined prostate cancer compared with prostate- specific antigen. Urology. 2000; 55: 481-5, CrossRef.
Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol. 2006; 13: 238-43, CrossRef.
Haese A, Graefen M, Steuber T, Becker C, Noldus J, Erbersdobler A, et al. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate-specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol. 2003; 170: 2269-73, CrossRef.
Steuber T, Vickers AJ, Haese A, Becker C, Pettersson K, Chun FK, et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: signiicant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate-specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer. 2006; 118: 1234-40, CrossRef.
Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003; 44: 8-16, CrossRef.
Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59: 5975-9, PMID.
de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002; 62: 2695-8, PMID.
Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol. 2012; 187: 795-801, CrossRef.
Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al. PCA3 score before radical prostatectomy predicts extrapcasular extension and tumor volume. J Urol. 2008; 180: 1975-8, CrossRef.
Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 2013; 64: 347-54, CrossRef.
Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ, et al. Evaluating the prostate cancer prevention trial high grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group. World J Urol. 2014; 32: 185-91, CrossRef.
van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P, et al. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer. 2012; 48: 1809-15, CrossRef.
Vickers AJ, Sjoberg DD, Ankerst DP, Tangen CM, Goodman PJ, Thompson IM Jr. The prostate cancer prevention trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer. 2013; 119: 3007-11, CrossRef.
Schmid M, Hansen J, Rink M, Fisch M, Chun F. The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy. Biomark Med. 2013; 7: 843-50, CrossRef.
Chun FK, Karakiewicz P, Huland H, Graefen M. Role of nomograms for prostate cancer in 2007. World J Urol. 2007; 25: 131-42, CrossRef.
Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A multicenter study of [-2]pro-prostate speciic antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011; 185: 1650-5, CrossRef.
Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014; 6: 74-7, CrossRef.
Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 2008; 6: 19, CrossRef.
Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse, Pollock BH, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008; 180: 1303-8, CrossRef.
Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Prostate cancer gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram. Eur Urol. 2009; 56: 659-68, CrossRef.
Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M, et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol. 2010; 58: 727-32, CrossRef.
Wu AK1, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2012; 15: 100-5, CrossRef.
Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, et al. Initial prostate biopsy: Development and internal validation of a biopsy-speciic nomogram based on the prostate cancer antigen 3 assay. Eur Urol. 2013; 63: 201-9, CrossRef.
McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell. 1992; 68: 283-302, CrossRef.
Martin NL, Saba-El-Leil MK, Sadekova S, Meloche S, Sauvageau G. EN2 is a candidate oncogene in human breast cancer. Oncogene. 2005; 24: 6890-901, CrossRef.
Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA. 2007; 104: 5527-32, CrossRef.
Lambert SR, Witt H, Hovestadt V, Zucknick M, Kool M, Pearson DM, et al. Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. Acta Neuropathol. 2013; 126: 291-3, CrossRef.
Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, et al. Engrailed-2 (EN2): A tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res. 2011; 17: 1090-8, CrossRef.
McGrath SE, Michael A, Morgan R, Pandha H. EN2: A novel prostate cancer biomarker. Biomark Med. 2013; 7: 893-901, CrossRef.
Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol. 2009; 6: 429-39, CrossRef.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644-8, CrossRef.
Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, et al. Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia. 2006, 8: 885-8, CrossRef.
Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Øyan AM, Haese A, et al. TMPRSS2:ERG fusion transcripts in urinefrom prostate cancer patients correlate with a less favorable prognosis. APMIS. 2009; 117: 575-82, CrossRef.
Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011; 3: 94ra72, CrossRef.
Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2–ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007; 13: 5103-8, CrossRef.
Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O. Urine TMPRSS2: ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate. 2013; 73: 242-9, CrossRef.
Falzarano SM, Magi-Galluzzi C. ERG protein expression as a biomarker of prostate cancer. Biomark Med. 2013; 7: 851-65, CrossRef.
Oon SF, Pennington SR, Fitzpatrick JM, Watson RW. Biomarker research in prostate cancer - towards utility, not futility. Nat Rev Urol. 2011; 8: 131-8, CrossRef.
Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol. 2005; 20: 1339-49, PMID.
Yasuda K, Nagakawa O, Akashi T, Fujiuchi Y, Koizumi K, Komiya A, et al. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate. 2009; 69: 346-51, CrossRef.
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst. 2005; 17: 114-20, PMID.
Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res. 2009; 15: 4292-8, CrossRef.
Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/ scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res. 2008; 14: 7385-90, CrossRef.
Nagakawa O, Yamagishi T, Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate. 2006; 66: 447-52, CrossRef.
Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, et al. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1137-41, CrossRef.
Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, et al. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer. 2012; 107: 840-6, CrossRef.
Robertson BW, Chellaiah MA. Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells. Exp Cell Res. 2010; 316: 1-11, CrossRef.
Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res. 1999; 5: 2271-7, PMID.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74, CrossRef.
Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett. 2010; 294: 139-46, CrossRef.
Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009; 19: 329-37, CrossRef.
Nagy JA, Chang SH, Shih S C, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010; 36: 321-31, CrossRef.
Zhang K, Waxman DJ. Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell derived tumor model. Mol CancerT her. 2013; 12: 787-98, CrossRef.
Tretiakova M, Antic T, Binder D, Kocherginsky M, Liao C, Taxy JB, et al. Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays. Hum Pathol. 2013; 44: 495-502, CrossRef.
van Niekerk CG, van der Laak JA, Börger ME, Huisman HJ, Witjes JA, Barentsz JO, et al. Computerized whole slide quantification shows increased microvascular density in pT2 prostate cancer as compared with normal prostate tissue. Prostate. 2009; 69: 62-9, CrossRef.
van Niekerk CG, Witjes JA, Barentsz JO, van der Laak JAWM, Hulsbergen van de Kaa CA. Microvascularity in transition zone prostate tumors resembles normal prostatic tissue. Prostate. 2013; 73: 467-75, CrossRef.
Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenield SA, Shen R, et al. Prospective study of prostate tumor angiogenesis and cancerspecific mortality in the health professionals follow up study. J Clin Oncol. 2009; 27: 5627-33, CrossRef.
Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol. 2010; 28: 687-92, CrossRef.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964-6, CrossRef.
Mund JA, Estes ML, Yoder MC, Ingram DA, Case J. Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells. Arterioscler Thromb Vasc Biol. 2012; 32: 1045-53, CrossRef.
Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, et al. Bone marrow derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 2007; 21: 1546-58, CrossRef.
Reeves F, Sapre N, Corcoran N, Hovens C. Tumor vascularity in prostate cancer: an update on circulating endothelial cells and platelets as noninvasive biomarkers. Biomark Med. 2013; 7: 879-91, CrossRef.
Gay LJ, Felding- Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11: 123-34, CrossRef.
Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011; 9: 237-49, CrossRef.
Erpenbeck L, Schön MP. Deadly allies: The fatal interplay between platelets and metastasizing cancer cells. Blood. 2010; 115: 3427-36, CrossRef.
Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008; 8: 1247-55, CrossRef.
Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal like transition and promotes metastasis. Cancer Cell. 2011; 20: 576-90, CrossRef.
Wong CK, Namdarian B, Chua J, Chin X, Speirs R, Nguyen T, et al. Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy. Br J Cancer. 2012; 107: 1564-73, CrossRef.
Wilson H. Changes in circulating tumor cell levels found to be accurate in predicting castration – resistant prostate cancer treatment. Biomark Med. 2013; 7: 919-21, CrossRef.
Seftel AD. Prostate cancer diagnosis is associated with an increased risk of erectile dysfunction after prostate biopsy. J Urol. 2012; 188: 2317-8, CrossRef.
Olmos D, Baird RD, Yap TA, Massard C, Pope L, Sandhu SK, et al. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res. 2011; 17: 5188-96, CrossRef.
Attard G, de Bono JS. Utilizing circulating tumor cells: Challenges and pitfalls. Curr Opin Genet Dev. 2011; 21: 50-8, CrossRef.
Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13: 2023-9, CrossRef.
Bednarz-Knoll N, Alix-Panabières C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res. 2011; 13: 228, CrossRef.
Velonas VM, Woo HH, Remedios CG, Assinder SJ. Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013; 14: 11034-60, CrossRef.
Shariat SF, Menesses-Diaz A, Kim IY, Muramoto M, Wheeler TM, Slawin KM. Tissue expression of transforming growth factorbeta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004; 63: 1191-7, CrossRef.
Shariat SF, Walz J, Roehrborn CG, Montorsi F, Jeldres C, Saad F, et al. Early postoperative plasma transforming growth factorbeta1 is a strong predictor of biochemical progression after radical prostatectomy. J Urol. 2008; 179: 1593-7, CrossRef.
Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med. 1995; 1: 282-4, CrossRef.
Grivennikov SI, Greten FR, Karin M. Immunity, inlammation, and cancer. Cell. 2010; 140: 883-99, CrossRef.
Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst. 2004; 96: 834-43, CrossRef.
Dabir PD, Ottosen P, Høyer S, Hamilton-Dutoit S. Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma. Diagn Pathol. 2012; 7: 81, CrossRef.
Shariat SF, Scherr DS, Gupta A, Bianco FJ Jr, Karakiewicz PI, Zeltser IS, et al. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol. 210;1 64: 681-94, PMID.
Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: A study of 761 cases. Hum Pathol. 2003; 34: 792-6, CrossRef.
Sita-Lumsden A, Fletcher CE, Dart DA, Brooke GN, Waxman J, Bevan CL. Circulating nucleic acids as biomarkers of prostate cancer. Biomark Med. 2013; 7: 867-77, CrossRef.
Ellinger J, Müller SC, Wernert N, von Ruecker A, Bastian PJ. Mitochondrial DNA in serum of patients with prostate cancer: A predictor of biochemical recurrence after prostatectomy. BJU Int. 2008; 102: 628-32, CrossRef.
Jerónimo C1, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G, et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene. 2001; 20: 5195-8, CrossRef.
Mehra N, Penning M, Maas J, van Daal N, Giles RH, Voest EE. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res. 2007; 13: 421-6, CrossRef.
Ellinger J, Müller DC, Müller SC, Hauser S, Heukamp LC, von Ruecker A, et al. Circulating mitochondrial DNA in serum: A universal diagnostic biomarker for patients with urological malignancies. Urol Oncol. 2012; 30: 509-15, CrossRef.
Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res. 2009; 15: 1032-8, CrossRef.
Müller I, Urban K, Pantel K, Schwarzenbach H. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia. Ann NY Acad Sci. 2006; 1075: 222-9, CrossRef.
Schwarzenbach H, Chun FK, Lange I, Carpenter S, Gottberg M, Erbersdobler A, et al. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer. 2007; 120: 1465-71, CrossRef.
Schwarzenbach H, Chun FK, Müller I, Seidel C, Urban K, Erbersdobler A, et al. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int. 2008; 102: 253-8, CrossRef.
Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009; 55: 559-67, CrossRef.
Altimari A, Grigioni AD, Benedettini E, Gabusi E, Schiavina R, Martinelli A, et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Res. 2008; 129: 756-62, CrossRef.
Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res. 2007; 13: 5361-7, CrossRef.
Papadopoulou E, Davilas E, Sotiriou V, Georgakopoulos E, Georgakopoulou S, Koliopanos A, et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann NY Acad Sci. 2006; 1075: 235-43, CrossRef.
Goessl C, Müller M, Miller K. Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer Prostatic Dis. 2000; 3: S17, CrossRef.
Ellinger J, Haan K, Heukamp LC, Kahl P, Büttner R, Müller SC, et al. CpG Island hypermethylation in cell-free serum DNA identiies patients with localized prostate cancer. Prostate. 2008; 68: 42-9, CrossRef.
Jerónimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002; 60: 1131-5, CrossRef.
Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N, et al. Promoter hypermethylation of GSTP1, AR, and 14-13-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate. 2007; 67: 427-32, CrossRef.
Bryzgunova OE, Morozkin ES, Yarmoschuk SV, Vlassov VV, Laktionov PP. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann NY Acad Sci. 2008; 1137: 222-5, CrossRef.
Chuang CK, Chu DC, Tzou RD, Liou SI, Chia JH, Sun CF. Hypermethylation of the CpG islands in the promoter region lanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect P. re2v007; 31: 59-63, CrossRef.
Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008; 179: 529-34, CrossRef.
Crocitto LE, Korns D, Kretzner L, Shevchuk T, Blair SL, Wilson TG, et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology. 2004; 64: 821-5, CrossRef.
Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res. 2001; 7: 2727-30, PMID.
Goessl C, Krause H, Müller M, Heicapell R, Schrader M, Sachsinger J, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily luids. Cancer Res. 2000; 60: 5941-5, PMID.
Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res. 2003; 9: 2673-7, PMID.
Jerónimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-conined prostate adenocarcinoma. J Natl Cancer Inst. 2001; 93: 1747-52, CrossRef.
Goessl C, Müller M, Heicappell R, Krause H, Straub B, Schrader M, et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology. 2001; 58: 335-8, CrossRef.
Woodson K, O'Reilly KJ, Hanson JC, Nelson D, Walk EL, Tangrea JA. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol. 2008; 179: 508-12, CrossRef.
Encyclopedia of Life Science [homepage on the Internet]. Microsatellite Instability; 2001 [cited 2014 Dec 1]. Available from: http://web.udl.es/.
Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005; 65: 8274-85, CrossRef.
Yuen HF, Chan YP, Cheung WL, Wong YC, Wang X, Chan KW. The prognostic significance of BMP-6 signaling in prostate cancer. Mod Pathol. 2008; 21: 1436-43, CrossRef.
Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res. 1996; 56: 218-22, PMID.
March-Villalba JA, Martínez-Jabaloyas JM, Herrero MJ, Santamaria J, Aliño SF, Dasí F. Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics. PLoS ONE. 2012; 7: e43470, CrossRef.
Zhang JS, Gong A, Cheville JC, Smith DI, Young CY. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer. 2005; 43: 249-59, CrossRef.
Bu H, Bormann S, Schäfer G, Horninger W, Massoner P, Neeb A, et al. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate. 2011; 71: 575-87, CrossRef.
Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, et al. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013; 73: 306-15, CrossRef.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843-54, CrossRef.
Heneghan HM, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol. 2010; 10: 543-50, CrossRef.
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fuids - the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011; 8: 467-77, CrossRef.
Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110: 13-21, CrossRef.
Hastings ML, Palma J, Duelli DM. Sensitive PCR-based quantitation of cell-free circulating microRNAs. Methods. 2012; 58: 144-50, CrossRef.
Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009; 69: 3356-63, CrossRef.
Nikitina EG, Urazova LN, Stegny VN. MicroRNAs and human cancer. Exp Oncol. 2012; 34: 2-8, PMID.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133: 647-58, CrossRef.
Yeh JH, Sidhu SS, Chan AC. Regulation of a late phase of T cell polarity and effector functions by Crtam. Cell. 2008; 132: 846-59, CrossRef.
Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1: 845-67, CrossRef.
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457: 910-4, CrossRef.
DOI: https://doi.org/10.18585/inabj.v6i3.26
Copyright (c) 2014 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
